Your browser is no longer supported. Please, upgrade your browser.
HCM Hutchison China MediTech Limited daily Stock Chart
HCM [NASD]
Hutchison China MediTech Limited
Index- P/E- EPS (ttm)-0.80 Insider Own6.60% Shs Outstand138.12M Perf Week-1.40%
Market Cap3.01B Forward P/E- EPS next Y-0.80 Insider Trans0.00% Shs Float59.26M Perf Month-0.64%
Income- PEG- EPS next Q-0.18 Inst Own30.65% Short Float1.67% Perf Quarter-6.48%
Sales204.89M P/S14.70 EPS this Y-16.20% Inst Trans- Short Ratio4.12 Perf Half Y-8.97%
Book/sh2.16 P/B10.10 EPS next Y14.00% ROA- Target Price34.52 Perf Year-20.11%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range14.74 - 30.30 Perf YTD-13.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-28.02% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low47.96% ATR1.08
Employees853 Current Ratio- Sales Q/Q0.40% Oper. Margin- RSI (14)55.66 Volatility6.53% 4.52%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume4.13 Prev Close21.21
ShortableYes LT Debt/Eq- EarningsMar 03 BMO Payout- Avg Volume240.30K Price21.81
Recom1.60 SMA200.82% SMA509.75% SMA200-1.19% Volume991,503 Change2.83%
Mar-13-20Initiated Cantor Fitzgerald Overweight
Feb-20-20Initiated Goldman Buy
Nov-19-19Initiated CLSA Buy
Oct-23-19Reiterated BofA/Merrill Buy $35 → $29
Jul-05-19Initiated Macquarie Outperform
May-29-20 08:00AM  Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20 GlobeNewswire
02:00AM  Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations GlobeNewswire
May-26-20 04:04AM  Chi-Med, BeiGene Join Forces For Solid Cancer Tumor Treatment SmarterAnalyst
02:00AM  Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab GlobeNewswire
May-14-20 02:00AM  Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program GlobeNewswire
May-11-20 12:17AM  SE Asia Stocks-Rise as China signals more policy measures to support economy Reuters
May-08-20 04:12AM  Chi-Med to Attend Upcoming Investor Conferences GlobeNewswire +6.45%
Apr-23-20 03:12AM  Should You Worry About Hutchison China MediTech Limited's (LON:HCM) CEO Pay? Simply Wall St.
Apr-22-20 08:15AM  Edison Issues ADR Update on Hutchison China MediTech (HCM) ACCESSWIRE +5.24%
04:00AM  Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings GlobeNewswire
Apr-17-20 07:35AM  The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement Benzinga
02:00AM  Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors GlobeNewswire
Apr-07-20 03:32PM  Do Hedge Funds Love Hutchison China MediTech Limited (HCM)? Insider Monkey
Mar-31-20 02:46AM  Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China GlobeNewswire
Mar-26-20 08:35AM  Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing PR Newswire
08:35AM  Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing CNW Group
Mar-16-20 08:35AM  International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020 PR Newswire -15.30%
Mar-10-20 08:35AM  International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020 CNW Group
Mar-05-20 12:00PM  Hutchison China MediTech (HCM) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Mar-03-20 10:26AM  Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs GlobeNewswire
Feb-25-20 02:15AM  Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 adjustment to announcement and presentation logistics due to travel restrictions GlobeNewswire
Feb-12-20 08:00PM  RPT-FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials Reuters
12:27PM  FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials Reuters
Feb-10-20 05:08AM  Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium GlobeNewswire
Feb-06-20 02:58AM  Chi-Med Announces the Exercise of Underwriters Over-allotment Option for Public Offering of ADSs GlobeNewswire
Jan-31-20 02:19AM  Chi-Med to Announce 2019 Final Results GlobeNewswire
Jan-23-20 11:52PM  Hutchison China MediTech Limited Just Released Its Third-Quarter Earnings: Here's What Analysts Think Simply Wall St. -9.93%
03:06AM  Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs GlobeNewswire
Jan-21-20 06:46PM  Chi-Med Announces Proposed Public Offering of ADSs GlobeNewswire
08:00AM  Moving Average Crossover Alert: Hutchison China MediTech Zacks
Jan-20-20 06:17AM  Will Hutchison China MediTech Continue to Surge Higher? Zacks
06:08AM  Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early GlobeNewswire
Jan-16-20 12:00PM  Hutchison China MediTech (HCM) Is Up 0.6% in One Week: What You Should Know Zacks
Jan-13-20 02:00AM  Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors GlobeNewswire
Jan-06-20 02:50AM  Chi-Med to Present at the 38th Annual JP Morgan Healthcare Conference GlobeNewswire
Dec-20-19 02:05AM  Chi-Meds New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China GlobeNewswire
Dec-14-19 06:39PM  Hedge Funds Arent Crazy About Hutchison China MediTech Limited (HCM) Anymore Insider Monkey
Dec-09-19 06:16AM  Highlights From The Deutsche Bank ADR Virtual Investor Conference Benzinga
Nov-29-19 07:35AM  Edison issues ADR update on Hutchison China MediTech (HCM) ACCESSWIRE
Nov-28-19 02:15AM  Chi-Meds Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China GlobeNewswire
Nov-25-19 02:15AM  Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors GlobeNewswire
Nov-22-19 08:00PM  Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting GlobeNewswire
Nov-15-19 08:35AM  Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing PR Newswire
01:01AM  How Much Of Hutchison China MediTech Limited (LON:HCM) Do Institutions Own? Simply Wall St.
Nov-11-19 02:15AM  Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors GlobeNewswire
Nov-06-19 08:35AM  International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 13th and 14th, 2019 PR Newswire
08:35AM  International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 13th and 14th, 2019 CNW Group
Oct-29-19 01:58PM  Hedge Funds Have Never Been This Bullish On Hutchison China MediTech Limited (HCM) Insider Monkey
Oct-17-19 02:45AM  Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers GlobeNewswire
Oct-10-19 07:45AM  Edison issues ADR update on Hutchison China MediTech (HCM) ACCESSWIRE
04:15AM  Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors GlobeNewswire
Oct-04-19 02:39AM  Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma GlobeNewswire
Oct-01-19 03:35AM  Investors Who Bought Hutchison China MediTech (LON:HCM) Shares Five Years Ago Are Now Up 152% Simply Wall St.
Sep-30-19 09:12AM  CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term GlobeNewswire
09:10AM  Hutchison China MediTech Solutions Enters Oversold Territory Zacks
07:16AM  CK Hutchison offers 1.3% of Chi-Meds share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term GlobeNewswire
Sep-29-19 11:00AM  Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting GlobeNewswire
Sep-25-19 02:15AM  Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting GlobeNewswire
Sep-18-19 02:15AM  Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting GlobeNewswire
Sep-16-19 09:39AM  Top Ranked Momentum Stocks to Buy for September 16th Zacks -6.02%
Sep-03-19 02:46AM  Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire -5.32%
02:25AM  Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma GlobeNewswire
Aug-26-19 12:54AM  Does Hutchison China MediTech Limited's (LON:HCM) CEO Pay Compare Well With Peers? Simply Wall St.
Aug-23-19 02:15AM  Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China GlobeNewswire
Aug-14-19 10:15AM  Edison issues ADR update on Hutchison China MediTech (HCM) ACCESSWIRE
Jul-30-19 02:41PM  Hutchison China MediTech Limited (HCM) Q2 2019 Earnings Call Transcript Motley Fool
04:43AM  Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs GlobeNewswire
Jul-19-19 03:16PM  Credit Suisse initiates coverage of AMC with optimistic outlook Yahoo Finance Video
Jul-17-19 08:38AM  FACTORIAL MANAGEMENT Ltd Buys Hutchison China Meditech GuruFocus.com
Jul-05-19 09:55AM  Edison Issues ADR Outlook on Hutchison China MediTech (HCM) ACCESSWIRE
Jul-03-19 02:00AM  Chi-Med to Announce 2019 Half-Year Financial Results GlobeNewswire
Jun-28-19 11:50AM  Why Chi-Med Stock Is Tanking Today Motley Fool -27.15%
05:33AM  Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares GlobeNewswire
Jun-27-19 05:37PM  Chi-Med Announces Secondary Offering of American Depositary Shares GlobeNewswire
Jun-18-19 01:56AM  Li Ka Shing-Backed Cancer Drug Developer Delays Launch of Hong Kong Listing Bloomberg +6.52%
Jun-14-19 04:00AM  Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early GlobeNewswire
May-17-19 08:35AM  Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing PR Newswire
May-10-19 12:00PM  International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15th and 16th, 2019 CNW Group
Apr-26-19 11:52AM  Did Hedge Funds Drop The Ball On Hutchison China MediTech Limited (HCM) ? Insider Monkey
Apr-15-19 09:36AM  Biotech group Chi-Med plans Hong Kong listing of up to $500 mln - sources Reuters
02:23AM  Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering GlobeNewswire
Apr-01-19 04:54AM  Chi-Med CEO: I don't lose sleep over IP concerns in China CNBC Videos
Mar-29-19 03:00AM  Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China GlobeNewswire
Mar-28-19 03:30AM  Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting GlobeNewswire
Mar-11-19 02:00AM  Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs GlobeNewswire
Feb-12-19 02:18AM  Chi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium GlobeNewswire +5.10%
Feb-08-19 02:34AM  Chi-Med to Announce 2018 Final Results GlobeNewswire
Jan-07-19 02:00AM  Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference GlobeNewswire
Dec-20-18 02:28AM  Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy GlobeNewswire -10.58%
02:00AM  Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company GlobeNewswire
Nov-29-18 10:10AM  BRIEF-Innovent Biologics Enters Global Collaboration Agreement With Hutchison China Meditech Reuters
03:00AM  Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors GlobeNewswire
Nov-26-18 02:00AM  Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®) GlobeNewswire +5.19%
Nov-16-18 02:00AM  Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China GlobeNewswire -17.60%
Oct-18-18 02:00AM  Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China GlobeNewswire
Sep-05-18 03:27AM  Boost for "made in China" medicine as Chi-Med wins key approval Reuters
02:00AM  Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China GlobeNewswire
Aug-22-18 10:06AM  Hutchison China Meditech CEO Emphasizes Seizing Opportunities Bloomberg
Jul-27-18 02:00PM  Hutchison China MediTech Limited Sponsored ADR to Host Earnings Call ACCESSWIRE
02:00AM  Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs GlobeNewswire
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for cancer and immunological diseases in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Bai Yun Shan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a MET inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523 for the treatment of hematological cancer and immunological diseases; HMPL-689 for the treatment of hematological cancer; HMPL-453 for the treatment of solid tumors; and HMPL-306 for the treatment of hematological malignancies, gliomas, and solid tumors, as well as epitinib and theliatinib, an EGFR inhibitor to penetrate the blood-brain barrier. Hutchison China MediTech Limited was founded in 2000 and is headquartered in Central, Hong Kong.